ZINACEF INJECTION - PWS IV 1.5GM/VIAL 1.5 G
CEFUROXIME SODIUM : 1.5 G · DIN 02213540 · GLAXOSMITHKLINE INC
Health Canada status: CANCELLED POST MARKET
What is ZINACEF INJECTION - PWS IV 1.5GM/VIAL?
ZINACEF INJECTION - PWS IV 1.5GM/VIAL 1.5 G contains CEFUROXIME SODIUM : 1.5 G. It is listed in the Health Canada Drug Product Database under DIN 02213540, held by GLAXOSMITHKLINE INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 09-Jul-2007. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ZINACEF INJECTION - PWS IV 1.5GM/VIAL used for?
Treatment of lower respiratory tract infections, urinary tract infections, soft tissue infections, meningitis, gonorrhoea, bone and joint infections. Pre-operative prophylaxis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02213540 |
|---|---|
| Brand name | ZINACEF INJECTION - PWS IV 1.5GM/VIAL |
| Generic / active ingredient | CEFUROXIME SODIUM : 1.5 G |
| Manufacturer | GLAXOSMITHKLINE INC |
| Strength | 1.5 G |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J01DC02 CEFUROXIME |
| AHFS class | 08:12.06.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 09-Jul-2007 |
| Original market date | 2002-01-01 00:00:00 |
How is it administered?
Adults: 750 mg to 1.5 g every 8 hours IV or IM. Meningitis: 3 g IV every 8 hours. Infants/Children: 30-100 mg/kg/day in 3-4 divided doses. Adjust dose in renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Dry state: Store below 25°C and protect from light. Reconstituted: Use within 6 hours at <25°C or 48 hours refrigerated.
How is it supplied?
750 mg in 17 mL vials (packs of 10); 1.5 g in 26 mL vials (packs of 10); 7.5 g Pharmacy Bulk Vials (packs of 6).
Contraindications
Contraindicated in patients with Type 1 hypersensitivity to cefuroxime or to the cephalosporin group of antibiotics.
Warnings and precautions
Check for hypersensitivity to cephalosporins/penicillins. Risk of pseudomembranous colitis. Potential for overgrowth of non-susceptible organisms. Risk of nephrotoxicity with concurrent diuretics.
What can be used instead?
Other Canadian products sharing ATC code J01DC02 CEFUROXIME. 9 of 44 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-CEFUROXIME | 250 MG | TABLET | APOTEX INC | MARKETED | DIN 02244393 |
| APO-CEFUROXIME | 500 MG | TABLET | APOTEX INC | MARKETED | DIN 02244394 |
| AURO-CEFUROXIME | 250 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02344823 |
| AURO-CEFUROXIME | 500 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02344831 |
| CEFTIN | 125 MG / 5 ML | GRANULES FOR SUSPENSION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02212307 |
| CEFUROXIME FOR INJECTION, USP | 1.5 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02241639 |
| CEFUROXIME FOR INJECTION, USP | 750 MG | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02241638 |
| JAMP CEFUROXIME | 250 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02547198 |
| JAMP CEFUROXIME | 500 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02547201 |
| CEFTIN - PWR 250MG/SACHET | 250 MG | POWDER | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 02212293 |
Who else supplies CEFUROXIME worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CEFUROXIME appears in 39 registered pack listings across 4 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.